Loading…

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis

Introduction Ruxolitinib (rux) treatment for myelofibrosis (MF) is frequently complicated by the development of thrombocytopenia, leading to dose reduction and treatment discontinuation, an event which is associated with poor outcomes. With the recent availability of JAK inhibitors that are safe and...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2023-11, Vol.142 (Supplement 1), p.1830-1830
Main Authors: Tremblay, Douglas, Schwabkey, Zaker I., Riazat-Kesh, Yosef Joseph Rene Amel, Van Hyfte, Grace, Al Ali, Najla H, Waksal, Julian, Srisuwananukorn, Andrew, Komrokji, Rami S., Mascarenhas, John, Kuykendall, Andrew T.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Ruxolitinib (rux) treatment for myelofibrosis (MF) is frequently complicated by the development of thrombocytopenia, leading to dose reduction and treatment discontinuation, an event which is associated with poor outcomes. With the recent availability of JAK inhibitors that are safe and effective in thrombocytopenic MF patients, identifying predictors for rux-induced thrombocytopenia may allow for personalized JAK inhibitor selection in the upfront setting. Methods We conducted a retrospective cohort study of JAK inhibitor naïve MF patients treated with rux at two large academic institutions (Mount Sinai and Moffitt Cancer Center). Included patients had a baseline platelet count of ≥100 x 10 9/L. The primary outcome was the development of a platelet count of
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-179937